OTC Valuations Limited, provider of independent derivatives valuation and risk reports for illiquid and hard-to-value securities, structured products, and exotic derivatives, has strengthened its team with the appointment of Dr. Paul Bergbusch to lead the organization’s technology function.
Paul comes to the OTC Val team from BlueCrest Capital Management, one of the largest hedge funds in Europe, he joins OTC Val as Chief Technology Officer, and will lead the effort to introduce the next generation of solutions further expanding the coverage for structured products and exotic derivatives under the OTC Val portfolio.
As an expert in financial derivatives and systems engineering, Dr. Bergbusch brings a wealth of data analysis, derivatives modeling and systems development experience for pricing and processing all derivatives products. He holds a Ph.D. in Experimental Particle Physics from the University of British Columbia.
"Before joining OTC Val I reviewed the market for independent derivatives valuations and realized that structured products and exotic derivatives are not being handled in a transparent and scalable way," Paul Bergbusch said, "The recent market turmoil and the push towards increasing regulation of the derivatives markets highlight the need for independent and transparent pricing."
Bob Sangha, COO, OTC Val, commented, "The fact that Paul joined OTC Val is also a great compliment to our service offering. His deep knowledge of data, models, and systems will enable OTC Val to deliver flexible and responsive solutions."
No comments:
Post a Comment